Urine MACC1 Plays an Indicative Role in Diagnosing Bladder Cancer

Hao Zi  
Huaihe Hospital of Henan University

Wen-Lin Tao  
Huaihe Hospital of Henan University

Lei Gao  
Huaihe Hospital of Henan University

Zhao-Hua Yu  
Huaihe Hospital of Henan University

Xiao-Dong Bai  
Huaihe Hospital of Henan University

Xiao-Dong Li (werbgdh@126.com)  
Huaihe Hospital of Henan University  https://orcid.org/0000-0002-8706-7624

Primary research

Keywords: Metastasis-associated in colon cancer 1, Bladder cancer, Diagnosis

DOI: https://doi.org/10.21203/rs.3.rs-86579/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Present study aimed to estimate the diagnostic efficacy of urine Metastasis-associated in colon cancer 1 (*MACC1*) for bladder cancer patients.

**Methods:** Urine *MACC1* expression was measured in bladder cancer patients and controls via quantitative real-time polymerase chain reaction (qRT-PCR) assay. Chi-square test was used to assess the correlation of urine *MACC1* levels with clinicopathological features of the patients. The diagnostic performance of urine *MACC1* was evaluated by receiver operating characteristics (ROC) curve.

**Results:** Urine *MACC1* was obviously elevated in bladder cancer patients compared with controls (*P*<0.001). What's more, abnormal urine *MACC1* expression was significantly correlated with differentiation (*P*=0.013), tumor stage (*P*=0.023), lymph node metastasis (*P*=0.033) and distant metastasis (*P*=0.026). Furthermore, according to ROC analysis, urine *MACC1* could distinguish bladder cancer patients from controls with an AUC (the areas under the ROC curve) of 0.909. The cut-off value of urine *MACC1* for bladder cancer diagnosis was 1.275, with 79.8% specificity and 87.3% sensitivity.

**Conclusion:** Urine *MACC1* may be act as a biomarkers for diagnosis of bladder cancer.

Background

Bladder cancer is one of the most frequently diagnosed malignancies in the urinary system around the world [1]. About 70–80% cases are confirmed as non-muscle-invasive (Ta and T1 tumors) bladder cancer (NMIBC), and the rest belongs to be muscle-invasive (T2-T4 tumors) bladder cancer (MIBC) [2]. Although the NMIBC is not life-threatening, with a five year-survival more than 90% [3]. However, approximate 50–70% of NMIBC will relapse, and 10–15% of them progress to MIBC within five-year of diagnosis [4]. Therefore, early diagnosis and postoperative monitoring are crucial for treatment and clinical outcomes of bladder cancer patients. At present, cystoscopy is the golden standard for early screening and monitoring of bladder cancer. However, the high cost and invasive procedures may limit its wide application [5]. Therefore, non-invasive biomarkers are in urgent need for patients with bladder cancer. The genetic materials, such as protein, DNA and RNA, derived from bladder tissues could be detected by easy methods in urine specimens that are considered as promising candidates for early detection and monitoring of bladder cancer [6, 7].

Metastasis-associated in colon cancer 1 (*MACC1*) initially detected in colon cancer [8] is confirmed a new cancer-related gene, located on human chromosome 7 (7p21.1). *MACC1* has the capacity to induce cell proliferation, migration and invasion [9, 10]. Moreover, numerous reports have proved that *MACC1* was highly expressed in human tumors, such as nasopharyngeal carcinoma, glioma, gastric cancer and so on [11–13]. In bladder cancer, Xu et al. reported that knockdown of *MACC1* using RNA interference could induce inhibition on proliferation and invasion of bladder cancer cells in vitro [14]. However, the expression patterns of urine *MACC1*, as well as its diagnostic efficacy for bladder cancer remained poorly known.
In the present study, we measured the expression status of \textit{MACC1} in urine samples collected from bladder cancer patients and non-malignant controls. Moreover, the relationship between urine \textit{MACC1} level and clinicopathological factors was also analyzed. In addition, the diagnostic value of urine \textit{MACC1} was evaluated in bladder cancer patient.

\textbf{Methods}

\textbf{Patients and sample collection}

The study was examined and approved by the Ethical Committee of Huaihe Hospital of Henan University. All participants signed written informed consents in the study.

118 patients who were newly diagnosed with bladder cancer were recruited from Huaihe Hospital of Henan University. Diagnosis of bladder cancer was based on pathological examinations. None of the patients had received any anti-tumor treatments. The demographic data and medical history of the patients were recorded in Table 1. Tumor classification was established according to Union for International Cancer Control (UICC) 2010 TNM system. At the same time, 104 age- and gender-matched subjects, including 92 healthy volunteers and 12 subjects with urolithiasis, were collected from the same hospital as controls.
Table 1
The relationship between circulating *MACC1* and clinicopathological variables of bladder cancer cases

| Variables                      | No. of case n = 118 | *MACC1* expression | χ²  | P value |
|-------------------------------|---------------------|--------------------|-----|---------|
|                               |                     | Low (n = 54)       |     |         |
|                               |                     | High (n = 64)      |     |         |
| Age (years)                   |                     |                    |     |         |
| < 53                          | 58                  | 25                 | 33  | 0.325   |
| >=53                          | 60                  | 29                 | 31  | 0.569   |
| Gender                        |                     |                    |     |         |
| Male                          | 92                  | 45                 | 47  | 1.670   |
| Female                        | 26                  | 9                  | 17  | 0.196   |
| Tumor size (cm)               |                     |                    |     |         |
| < 3.75                        | 67                  | 32                 | 35  | 0.249   |
| >=3.75                        | 51                  | 22                 | 29  | 0.617   |
| Differentiation               |                     |                    |     |         |
| High-moderate                 | 51                  | 30                 | 21  | 6.173   |
| Low                           | 67                  | 24                 | 43  | 0.013   |
| Tumor stage                   |                     |                    |     |         |
| Ta-T1                         | 48                  | 28                 | 20  | 5.151   |
| T2-T4                         | 70                  | 26                 | 44  | 0.023   |
| Lymph node metastasis         |                     |                    |     |         |
| Negative                      | 53                  | 30                 | 23  | 4.556   |
| Positive                      | 65                  | 24                 | 41  | 0.033   |
| Distant metastasis            |                     |                    |     |         |
| Absent                        | 42                  | 25                 | 17  | 4.975   |
| Present                       | 76                  | 29                 | 47  | 0.026   |

Urine samples were collected from each participant in the morning, and then centrifuged at 600 × gravity for 5 minutes at 4°C. Supernatant was decanted, aliquoted into Eppendorf tubes and maintained at -80°C until use.
RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from urine samples using TRIzol reagent (Invitrogen, Grand Island, NY, USA) based on the protocols of the manufacturer. The concentration and purity of RNA were measured at 260 and 280 nm with BioPhotometer plus (Eppendorf AG, Hamburger, Germany).

Then the first chain of cDNA was generated by reverse transcription utilizing the HiFi-MMLV cDNA Kit (Beijing CoWin Biotech Co. Ltd., Beijing, China) according to the instruction of the manufacturer. QRT-PCR was carried out using a SYBR green I Master Mix kit (Invitrogen). The primers sequence was synthesized according to the previous report [14]. β-actin was employed as reference control. The expression of MACC1 gene was normalized to the internal control, and calculated using 2^{-ΔΔCt} method. Each test was repeated at least three times.

Statistical analysis

All statistical analyses were carried out using SPSS version 18.0 (SPSS, Chicago, USA), and graphs were plotted by GraphPad Prism 5.0 (GraphPad Software). The statistical differences of MACC1 expression between bladder cancer patients and controls were assessed via independent Student t test. Chi-square test was applied to analyze the association of urine MACC1 with clinicopathological features of bladder cancer patients. The diagnostic capacity of urine MACC1 for bladder cancer was evaluated by receiver operating characteristics (ROC) curve. The specificity and sensitivity, as well as the area under the curve (AUC) value were calculated to estimate the diagnostic performance of urine MACC1 for bladder cancer. P value less than 0.05 was regarded as statistical significance.

Results

Baseline characteristics of the bladder cancer patients

A total of 118 bladder cancer patients including 92 males and 26 females were included in our study, and their average age was 58.76 ± 10.56 years. 51 patients had tumor size more than 3.75 cm. The pathological examinations suggested that 67 patients exhibited low differentiation, and 51 patients exhibited high and moderate differentiation. According to TNM staging system, 48 patients were diagnosed with stages Ta-T1, and 65 patients diagnosed with stages T2-T4. Lymph node metastasis was observed in 65 patients, while distant metastasis was observed in 76 patients. The clinical information of the included patients were summarized in Table 1.

Urine MACC1 level in bladder cancer patients

We analyzed the expression levels of MACC1 mRNA in urine samples of 118 bladder cancer patients and 104 controls. According to qRT-PCR assay, urine MACC1 levels were dramatically up-regulated in bladder cancer patients, compared to the controls (P< 0.001, Fig. 1).
Association of urine MACC1 with clinicopathological parameters

To further analyze the relationship between urine MACC1 levels and clinicopathological parameters, we divided all patients into two groups based on the median value of urine MACC1 expression: low MACC1 expression group (n = 54) and high MACC1 expression group (n = 64). As indicated in Table 1, the elevated urine MACC1 expression was distinctly correlated with bladder cancer patients’ differentiation (P = 0.013), tumor stage (P = 0.023), lymph node metastasis (P = 0.033), and distant metastasis (P = 0.026). Nevertheless, urine MACC1 levels had no association with other clinicopathological factors, such as age, gender, or tumor size (all P > 0.05).

Diagnostic performance of urine MACC1 in bladder cancer

ROC curve analysis illustrated that urine MACC1 could distinguish bladder cancer patients from healthy controls with an AUC (the areas under the ROC curve) of 0.909 (95%CI: 0.872-946) (Fig. 2). At a cutoff value of 1.275, the optimal specificity and sensitivity values were 79.8%, and 87.3%, respectively (Fig. 2).

Discussion

Bladder cancer is a heterogeneous disease with unpredictable clinical course, representing a leading cancer-related deaths [15]. At present, there are several major risk factors identified in bladder cancer, such as cigarette smoking, chronic infection by Schistosoma haematobium, and exposure to the carcinogens [16, 17]. Early diagnosis and close monitoring are key for clinical outcomes of patients with bladder cancer. Unfortunately, there are no recommended biomarkers for bladder cancer in routine clinical application until now [18]. In current study, we confirmed that the expression profiles of urine MACC1 were significantly different between bladder cancer patients and non-malignant individuals. Urine MACC1 might be a potential diagnostic biomarker for bladder cancer.

MACC1 encodes a protein containing four domains: ZU5, SH3 and two C-terminal death domains [19]. Growing evidences have demonstrated that the over-expression of MACC1 may contribute to malignant tumor progression through enhancing cell proliferation, migration and invasion [8, 20–22]. The expression pattern of MACC1 in human fluids may have the possible to serve as a biomarker for early diagnosis and prognosis evaluation in several types of human cancers. For instance, Ashkorab et al. reported that MACC1 transcripts were obviously increased in plasma samples of colon adenoma patients compared with normal patients. Moreover, plasma MACC1 could distinguish the colon adenoma patients from healthy individuals [23]. Tan et al. showed that serum MACC1 was highly expressed in breast cancer patients, and it might be a reliable biomarker for early diagnosis and prognosis evaluation in breast cancer patients [24]. A study carried out by Wang et al., reported that plasma MACC1 expression exhibited significantly increased in non-small cell lung cancer patients, and might be a promising non-invasive factor for diagnosis and prognosis of the disease [25]. Taken together, the expression of MACC1 in human fluids shows specific to cancer, which may be employed as biomarker for diagnosis and
monitoring of cancer. However, the clinical significance of urine MACC1 in bladder cancer was rarely reported.

In this study, urine MACC1 mRNA expression was examined in bladder cancer patients and controls using qRT-PCR method. The expression of MACC1 was significantly increased in urine samples of bladder cancer patients in comparison to controls. The result was in line with the previous study reported by Xu et al., revealing that MACC1 mRNA levels were up-regulated in human urothelial carcinoma [14]. In addition, we estimated the association of urine MACC1 expression with clinicopathological parameters of bladder cancer patients. The abnormal MACC1 expression in urine samples was remarkably associated with tumor differentiation, tumor stage, lymph node metastasis, and distant metastasis. The bladder cancer patients with high expression of MACC1 were more likely to undergo malignant disease progression. The in vitro experiments carried out by Xu et al. suggested that MACC1 could regulate the biological behaviors of human bladder urothelial carcinoma cell line T24 [14]. Over-expression of MACC1 might contribute to progression of bladder cancer through enhancing the malignant biological behaviors of cancer cells.

Given the different levels of urine MACC1 in bladder cancer cases and healthy individuals, we hypothesized that urine MACC1 might be a potential diagnostic biomarker for bladder cancer. ROC curves were plotted to estimate the diagnostic performance of urine MACC1 in bladder cancer. Urine MACC1 could distinguish bladder cancer patients from the non-malignant controls with high sensitivity and specificity. Urine MACC1 might act as a valid and reliable biomarker for early screening of patients suffering from bladder cancer.

This study had certain limitations. Firstly, the number of patients recruited in the study was relatively small, and further studies with a large scale number of patients are required to confirm our findings. Secondly, the patients corrected in our study all came from one hospital that might cause bias to our results. In addition, the molecular mechanisms underlying the oncogenic function of MACC1 remained poorly known. Further in vitro and in vivo experiments are required to address the issues. Therefore, multicenteric studies should be considered to verify the value of MACC1 as a diagnostic biomarker for bladder cancer.

**Conclusions**

In conclusion, urine MACC1 level is up-regulated in bladder cancer patients and closely associated with tumor metastasis and progression. Urine MACC1 may be a valuable biomarker for early screening of bladder cancer.

**List Of Abbreviations**

Metastasis-associated in colon cancer 1 (MACC1)

Quantitative real-time polymerase chain reaction (qRT-PCR)
Receiver operating characteristics (ROC)

Non-muscle-invasive (Ta and T1 tumors) bladder cancer (NMIBC)

Muscle-invasive (T2-T4 tumors) bladder cancer (MIBC)

Union for International Cancer Control (UICC)

Area under the curve (AUC)

Declarations

Ethics approval and consent to participate

This study was supported by the Ethics Committee of Huaihe Hospital of Henan University and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

Consent for publication

We obtaining permission from participants to publish their data.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors’ contributions

H.Z., X.L. design of the work; W.T. the acquisition, analysis, L.G. interpretation of data; Z.Y. the creation of new software used in the work; X.B. have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.
References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F: Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European urology 2017, 71(1):96-108.

2. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M et al: EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European urology 2017, 71(3):447-461.

3. Miyake M, Owari T, Hori S, Nakai Y, Fujimoto K: Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Research and reports in urology 2018, 10:251-261.

4. Amuran GG, Eyuboglu IP, Tinay I, Akkiprik M: New Insights in Bladder Cancer Diagnosis: Urinary miRNAs and Proteins. Med Sci (Basel) 2018, 6(4).

5. Kutwin P, Konecki T, Cichocki M, Falkowski P, Jablonsowski Z: Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review. Photomedicine and laser surgery 2017, 35(9):459-464.

6. Santoni G, Morelli MB, Amantini C, Battelli N: Urinary Markers in Bladder Cancer: An Update. Frontiers in oncology 2018, 8:362.

7. Leiblich A: Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer. Current urology reports 2017, 18(12):100.

8. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature medicine 2009, 15(1):59-67.

9. Wang Y, Hong Q, Wang J, Fang Y, Hu C: Downregulated expression of metastasis associated in colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014, 35(4):3771-3778.

10. Wang G, Kang MX, Lu WJ, Chen Y, Zhang B, Wu YL: MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncology letters 2012, 4(4):783-791.

11. Meng F, Li H, Shi H, Yang Q, Zhang F, Yang Y, Kang L, Zhen T, Dai S, Dong Y et al: MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PloS one 2013, 8(4):e60821.

12. Yang T, Kong B, Kuang YQ, Cheng L, Gu JW, Zhang JH, Shu HF, Yu SX, He WQ, Xing XM et al: Overexpression of MACC1 protein and its clinical implications in patients with glioma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014, 35(1):815-819.

13. Lin L, Huang H, Liao W, Ma H, Liu J, Wang L, Huang N, Liao Y: MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect. Oncogene 2015, 34(21):2700-2710.
14. Xu ST, Ding X, Ni QF, Jin SJ: Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells. *International journal of clinical and experimental pathology* 2015, 8(7):7937-7944.

15. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. *CA: a cancer journal for clinicians* 2017, 67(1):7-30.

16. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT et al: Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. *European urology* 2018, 74(6):784-795.

17. Fankhauser CD, Mostafid H: Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. *Current opinion in urology* 2018, 28(1):88-92.

18. DeGeorge KC, Holt HR, Hodges SC: Bladder Cancer: Diagnosis and Treatment. *American family physician* 2017, 96(8):507-514.

19. Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LS: Unexpected domain composition of MACC1 links MET signaling and apoptosis. *Acta biochimica Polonica* 2009, 56(2):317-323.

20. Li HF, Liu YQ, Shen ZJ, Gan XF, Han JJ, Liu YY, Li HG, Huang ZQ: Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma. *Oncology reports* 2015, 33(2):651-660.

21. Wu J, Zhang D, Li J, Deng X, Liang G, Long Y, He X, Dai T, Ren D: MACC1 induces autophagy to regulate proliferation, apoptosis, migration and invasion of squamous cell carcinoma. *Oncology reports* 2017, 38(4):2369-2377.

22. Qian LQ, Li XQ, Ye PH, Su HY, Wang G, Liu Y, Shen GH, Gao QG: Downregulation of MACC1 inhibits the viability, invasion and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway. *Oncology letters* 2017, 14(4):4897-4905.

23. Ashktorab H, Hermann P, Nouraie M, Shokrani B, Lee E, Haidary T, Brim H, Stein U: Increased MACC1 levels in tissues and blood identify colon adenoma patients at high risk. *Journal of translational medicine* 2016, 14(1):215.

24. Tan W, Xie X, Li L, Tang H, Ye X, Chen L, Tang W, Gao J, Pan L, Zhang X et al: Diagnostic and prognostic value of serum MACC1 in breast cancer patients. *Oncotarget* 2016, 7(51):84408-84415.

25. Wang Z, Cai M, Weng Y, Zhang F, Meng D, Song J, Zhou H, Xie Z: Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer. *Journal of cancer research and clinical oncology* 2015, 141(8):1353-1361.

Figures
Expression of urine MACC1 determined by qRT-PCR assay in bladder cancer patients and controls. Urine MACC1 levels were significantly increased in bladder cancer patients compared with controls (***: P<0.001).
Expression of urine MACC1 determined by qRT-PCR assay in bladder cancer patients and controls. Urine MACC1 levels were significantly increased in bladder cancer patients compared with controls (***, P<0.001).
Receiver operating characteristics (ROC) curve analysis for the diagnostic accuracy of urinary MACC1 in bladder cancer. The AUC (areas under the ROC curve) value was 0.909 (95%CI: 0.872-0.946). The specificity and sensitivity were 79.8% and 87.3%, respectively. All the data revealed that urine MACC1 could distinguish bladder cancer patients from the controls, and the cut-off value was 1.275.
Figure 2

Receiver operating characteristics (ROC) curve analysis for the diagnostic accuracy of urinary MACC1 in bladder cancer. The AUC (areas under the ROC curve) value was 0.909 (95%CI: 0.872-0.946). The specificity and sensitivity were 79.8% and 87.3%, respectively. All the data revealed that urine MACC1 could distinguish bladder cancer patients from the controls, and the cut-off value was 1.275.